Company Overview and News


Add STAGR
to your dashboard

Headline News

Global Allergy Treatment Market: High Unmet Needs in Emerging Economies to Boost Market, Finds TMR

2017-08-07 prnewswire
A recent intelligence study by Transparency Market Research (TMR) has detected that the global allergy treatment market is dominated by ALK-Abelló A/S when it comes to immunotherapy, whereas GlaxoSmithKline plc. Holds the pole position in the market in terms of anti-allergic drugs. The positions hold true for the base year of this report, the end of the year 2016. The stronghold of these two companies over the global allergy treatment market is primarily attributed to their impressive product portfolio and widespread geographical presence.

Stallergenes Greer Announces Completion of Enrollment in Largest Phase III Study to Treat House Dust Mites Allergy

2017-07-27 londonstockexchange
Stallergenes Greer (Paris:STAGR), a biopharmaceutical company specialising in treatments for respiratory allergies, announced today that it completed enrollment in a pivotal Phase III clinical study to evaluate the safety and efficacy of its investigational sublingual immunotherapy tablet STG320 for the treatment of house dust mite (HDM) induced allergic rhinitis. The study recruited over 1,600 patients from 13 countries with 231 participating investigative sites, and is the largest study of its kind.

Global Allergic Rhinitis Drugs Market 2017-2027

2017-07-05 prnewswire
Report Details The global allergic rhinitis drugs market is expected to grow at a CAGR of 3.2% in the first half of the forecast period. The market is expected to grow at a CAGR of 3.3% from 2016-2027. The market is estimated at $11.9bn in 2016 and $13.9bn in 2021. Read the full report: http://www.reportlinker.com/p04974738/Global-Allergic-Rhinitis-Drugs-Market.html How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.

Stallergenes Greer Announces Matthias Vogt as Chief Financial Officer

2017-06-29 londonstockexchange
Stallergenes Greer plc (Paris:STAGR) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, announced today the appointment of Matthias Vogt as its Chief Financial Officer (CFO), effective as of October 1st. Matthias Vogt will lead Stallergenes Greer’s global Finance function. He will report directly to Fereydoun Firouz, Chairman and CEO of Stallergenes Greer, and will be based in London.

Stallergenes Greer Announces Change of Auditor

2017-06-20 londonstockexchange
Stallergenes Greer (Paris:STAGR), a biopharmaceutical company specialising in treatments for respiratory allergies, announces that following the completion of a formal audit tender process, conducted in accordance with the relevant requirements and led by the Company's Audit Committee, the Board has approved the appointment of EY LLP as the Company's auditor for the financial year commencing 1 January 2017.

Stallergenes Greer plc:?First Real-World Evidence Shows Long Term Benefits of Sublingual Immunotherapy to Control Allergic Rhinitis and Potentially Prevent Allergic Asthma

2017-06-19 londonstockexchange
Stallergenes Greer (Paris:STAGR), a biopharmaceutical company specialising in treatments for respiratory allergies, announced positive results from a real-world evidence (RWE) study on the long-term effectiveness of grass pollen sublingual immunotherapy (SLIT) treatment vs. symptomatic drugs. This is the first study that is based on eight years’ worth of data to demonstrate the long-term effectiveness of SLIT tablets including Stallergenes Greer’s tablet ORALAIR®.

Stallergenes Greer Shareholders Approve All Resolutions Proposed by the Board of Directors at the Annual General Meeting

2017-06-08 londonstockexchange
Stallergenes Greer Plc (Paris:STAGR) (Euronext Paris: STAGR), a biopharmaceutical company specialising in treatments for respiratory allergies, announces that all resolutions proposed by the Board of Directors at the company’s Annual General Meeting (AGM) were duly passed today. All resolutions were set out in the Notice of Meeting posted to shareholders on 3 May 2017.

AGM Statement

2017-05-03 londonstockexchange
The shareholders of Stallergenes Greer plc (the “Company”) (Paris:STAGR) (Euronext Paris: STAGR), a biopharmaceutical company specialising in treatments for respiratory allergies, are hereby informed that they are invited to attend the Annual General Meeting at Palais Brongniart, 28 Place de la Bourse, 75002 Paris, France, on 8 June 2017 at 2:00p.m. (CET).

Stallergenes Greer Announces Publication of Its 2016 Annual Report

2017-04-28 londonstockexchange
Stallergenes Greer (the “Company”) (Paris:STAGR) (Euronext Paris: STAGR), a biopharmaceutical company specialising in treatments for respiratory allergies, today announces the publication of its 2016 Annual Report.

Stallergenes Greer Announces Submission of New Drug Application for Pediatric Use of ACTAIR? in Japan

2017-03-28 londonstockexchange
Stallergenes Greer (the “Company”) (Paris:STAGR) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced that its commercialization partner in Japan, Shionogi & Co. Ltd. (Shionogi), submitted its New Drug Application (NDA) for ACTAIR®, an investigational allergy immunotherapy sublingual tablet for the treatment of house dust mite (HDM) induced allergic rhinitis in children 5 to 11 years old.

Stallergenes Greer plc: Notification to Shareholders of Transaction by Person Discharging Managerial Responsibilities or Person Closely Associated with Them

2017-02-06 londonstockexchange
Stallergenes Greer plc (the “Company”) (Paris:STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, has today sent a notice to shareholders, the full table of which is set out below.

Allergy Diagnostics Market by Product, Consumables, Services, Allergen, Tests, End User - Forecast to 2021

2017-01-31 prnewswire
NEW YORK, Jan. 31, 2017 /PRNewswire/ -- The allergy diagnostics market is expected to reach USD 5.34 billion by 2021 from USD 2.98 billion in 2016, at a CAGR of 12.4%. The global allergy diagnostics market is segmented based on product, allergen, test, end user, and region. The assay kits segment is expected to register the highest growth rate in the allergy diagnostics market, by product, during the forecast period.

Stallergenes Greer Announces Resignation of Chief Financial Officer

2017-01-31 londonstockexchange
Stallergenes Greer plc (the “Company”) (Paris:STAGR) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced that Peter Bühler has resigned as Chief Financial Officer. His last day will be April 28, 2017.

Stallergenes Greer Announces Positive Top-Line Results of Phase 3 Study for Pediatric House Dust Mite-Induced Allergic Rhinitis

2017-01-27 londonstockexchange
Stallergenes Greer (the “Company”) (Euronext Paris: STAGR) (Paris:STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced positive topline results for a Phase 3 clinical study of its sublingual immunotherapy tablet (STG320) for the treatment of house dust mite (HDM) induced allergic rhinitis in the pediatric population, which was conducted in Japan by its partner Shionogi & Co.

Allergy Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

2016-12-09 prnewswire
LONDON, Dec. 8, 2016 /PRNewswire/ -- Allergy Diagnostics Market: Scope and Methodology Allergy diagnostics includes products and tests that are used to determine the presence of allergens such as grass, weed, peanuts, milk, or drugs etc. in the samples by determining the presence of antibodies developed by the immune system. The report on global allergy diagnostics market, analyzes the current and future prospects of the market.